
Hosted by Sal Daher
In the Decade of Biotech when there will be myriad opportunities to invest in angel-scale biotech startups. After decades of angel investing, I am focusing on the life science side of my portfolio and invite other angels to do the same. Here's why: I'm Sal Daher, host of the Angel Invest Boston Podcast.
311 episodes · publishes weekly · latest 2023-12-29 · ~40 min/episode
Rank
#657
Substance
75.0
/ 100
Breakdown
Scored 2026-07
Updated monthly
Across the index
#657 of 6183
Substance
Top 11%
outscores 89% of the index
Angel Invest Boston ranks #657 on The B2B Podcast Index with a substance score of 75.0 out of 100, scored across 1 recent episode. It scores highest on guest caliber and specificity & evidence. The clip roster is genuinely strong: Howard Stevenson (co-founded Baupost, pioneered entrepreneurship study at HBS), Ed Roberts (MIT Sloan with large longitudinal datasets), Chuck Easley (Stanford, replicated findings across MIT/Stanford/Tsinghua data), and Wistia's real operating founders. These are practitioners and researchers who have actually done the work at scale, not career speaking-circuit guests.
Averaged across 1 recently scored episode, with cited evidence.
The episode mixes a few genuinely non-obvious observations - particularly the idiosyncratic upside-skew of private assets vs. public markets, and the personal confession that the host's highest-conviction bets almost all failed - with a large volume of standard startup-wisdom platitudes (team matters, focus, share your ideas). The lesson density is moderate for a 39-minute compilation.
“Private assets such as startups, however, are more likely to experience upside surprise than traded assets. Since the value of their shares are not exposed to price discovery by an active market, a startup can be killing it, and few people beyond the investors may be aware of that success.”
“I have learned I cannot pick winners. There were some companies I felt had such a compelling team and product that they were slam dunks. I invested more in them and put them in my Roth IRA post tax money. Almost every single one of them failed.”
The framing of startup idiosyncratic risk as tilted to the upside (inverse of public markets) is a genuinely fresh angle, and the host's honest admission of his own pattern of failed high-conviction bets is refreshingly candid. Everything else - team over plan, focus, share your idea, more founders is better - is widely circulated startup doctrine.
“idiosyncratic risk is seriously tilted to the downside. Private assets such as startups, however, are more likely to experience upside surprise”
“I have learned I cannot pick winners”
The clip roster is genuinely strong: Howard Stevenson (co-founded Baupost, pioneered entrepreneurship study at HBS), Ed Roberts (MIT Sloan with large longitudinal datasets), Chuck Easley (Stanford, replicated findings across MIT/Stanford/Tsinghua data), and Wistia's real operating founders. These are practitioners and researchers who have actually done the work at scale, not career speaking-circuit guests.
“Howard Stevenson was a pioneer of the study of entrepreneurship at the Harvard Business School...He helped found one of the top hedge funds, the Baupost Group.”
“we replicate that same finding among Stanford alumni and even the international data sets that I've collected in China of the Tsinghua University alumni”
The episode delivers several concrete, named data points: Asurion's 400x return and its cell-phone insurance business model, Howard Stevenson's exact portfolio return figures (17-18%, 12% without the outlier), and the host's own SQZ Biotech investment ($50K → $500K+ → $0) with IPO date. Ed Roberts' statistically significant founder-count findings add empirical weight.
“we probably return 17 or 18%, probably 12% without the real big winner.”
“My $50,000 investment was was worth more than $500,000. Eventually I thought about selling down my position but never got around to doing it...my stake became worthless.”
This is primarily a curated compilation rather than a live interview, so conversational dynamic is limited. The embedded clip questions are mostly setup-and-listen, though there are occasional moments of genuine pushback (pressing Ed Roberts on whether he has data for the idea-sharing claim). The host's curation and framing between clips is coherent but rarely probing.
“So what, you have data to show that?”
“So when they show you a business plan, you expect to make money from something else they're going to come up with. So you better have a team that can come up with something that really can work.”
2023-12-29
First period on the Index - history builds from here.
1 scored on substance · 60 tracked in total.
Add this badge to your site - it links back here and updates automatically as you rank.
<a href="https://index.fame.so/show/angel-invest-boston" target="_blank" rel="noopener">
<img src="https://index.fame.so/badge/angel-invest-boston/badge.svg" alt="Ranked #102 on The B2B Podcast Index" width="360" height="136" />
</a>Track Angel Invest Boston's rank
Get an email whenever this show moves up or down the Index. Monthly at most, no spam.
The themes that come up most across this show's episodes.
Podcasts that dig into the same topics.